Phase 2a study of copanlisib, a novel phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with relapsed/refractory, idolent or aggressive lymphoma

Kim Linton, George Follows, Martin Dreyling, Julia Grunert, Florian Hiemeyer, Marius Giurescu, Barrett H. Childs, David Cunningham

    Research output: Contribution to conferenceOther

    Original languageEnglish
    Publication statusPublished - 2015
    EventBritish Society for Haematology 55th Annual Scientific Meeting - Edinburgh
    Duration: 20 Apr 201522 Apr 2015

    Conference

    ConferenceBritish Society for Haematology 55th Annual Scientific Meeting
    CityEdinburgh
    Period20/04/1522/04/15

    Cite this